please contact sales@tanchin.hk for any inquiry
On February 1, surging news reporters learned from Gilead science that the clinical trial of its new drug remdesivir in the treatment of new coronavirus (2019 ncov) pneumonia will be launched in Beijing China Japan Friendship Hospital on February 3.
It is reported that Gilead will cooperate with China's health sector to carry out a randomized, controlled trial to determine whether the use of remdesivir in the treatment of 2019 ncov infected people is safe and effective.
Remdesivir is a nucleotide analogue prodrug that inhibits RNA dependent RNA synthetase (RdRp). The drug, originally developed for Ebola, has just been shown to be effective against pneumonia caused by the new coronavirus in a case in the United States.
On January 31 local time, the top medical journal New England Medicine published the detailed diagnosis and treatment process of a 30-year-old man infected with the new coronavirus pneumonia in the United States.


please contact sales@tanchin.hk for any inquiry
PREVIOUS:Bearing side cover packing Improvement        

2 X 7209 BECBM DF 2 X 7209 BECBJ DT 2 X 7209 BECBJ DB 2 X 7209 BECBJ DF 2 X 7408 BGBM DT 2 X 7408 BGBM DB 2 X 7408 BGBM DF 2 X 7408 BCBM DT 2 X 7408 BCBM DB 2 X 7408 BCBM DF 2 X 7308 BEGBY DT 2 X 7308 BEGBY DB 2 X 7308 BEGBY DF 2 X 7308 BEGBP DT 2 X 7308 BEGBP DB 2 X 7308 BEGBM DT 2 X 7308 BEGBM DB 2 X 7308 BEGBM DF 2 X 7308 BEGAP DT 2 X 7308 BEGAP DB